Ardelyx (ARDX) announced the approval of a New Drug Application, NDA, by China’s Center for Drug Evaluation of the National Medical Products Administration for tenapanor to control serum phosphorus levels in dialysis patients with chronic kidney disease who have an inadequate response or are intolerant to phosphorus binders.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDX:
- Ardelyx (ARDX) Earnings Call: Strong Growth Amidst Challenges
- Ardelyx price target lowered to $13 from $15 at Raymond James
- Ardelyx Inc. Grapples with Trade Secret Risks Threatening Financial Stability
- Ardelyx Reports Strong 2024 Financial Performance
- Biotech Alert: Searches spiking for these stocks today